Welcome to CDC stacks | Notes from the Field: Acquisition of Delamanid Under a Compassionate Use Program for Extensively Drug-Resistant Tuberculosis — United States, 2017 - 59349 | Morbidity and Mortality Weekly Report (MMWR)
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Notes from the Field: Acquisition of Delamanid Under a Compassionate Use Program for Extensively Drug-Resistant Tuberculosis — United States, 2017
Filetype[PDF-131.78 KB]


Details:
No Related Documents.
You May Also Like:
  1. MMWR. Morbidity and mortality weekly report, Vol. 67, no. 35, September 7, 2018
    Corporate Author:
    Centers for Disease Control and Prevention (U.S.)
    Published:
    September 7, 2018
    Series:
    MMWR. Morbidity and mortality weekly report ; v. 67, no. 35
    Description:
    National Preparedness Month — September 2018 -- Assessment of State, Local, and Territorial Zika Planning and Preparedness Activities — United States, June 2016–July 2017 / Bhavini Patel Murthy, MD; Sara Vagi, PhD; Rodel Desamu-Thorpe, MD; et a...
    File Type:
    Filetype[PDF - 1020.13 KB]
  2. National Preparedness Month — September 2018
    Published:
    Sep 07 2018
    Source:
    MMWR Morb Mortal Wkly Rep. 67(35):969.
    Series:
    National Preparedness Month
    File Type:
    Filetype[PDF - 118.50 KB]
  3. Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis
    Personal Author:
    Mbuagbaw, Lawrence; Guglielmetti, Lorenzo; Hewison, Catherine; Bakare, Nyasha; Bastard, Mathieu; Caumes, Eric; Fréchet-Jachym, Mathilde; Robert, Jérôme; Veziris, Nicolas; Khachatryan, Naira; Kotrikadze, Tinatin; Hayrapetyan, Armen; Avaliani, Zaza; Schünemann, Holger J.; Lienhardt, Christian;
    Published:
    May 2019
    Source:
    Emerg Infect Dis. 25(5):936-943
    Description:
    Bedaquiline is recommended by the World Health Organization for the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB). We pooled data from 5 cohorts of patients treated with bedaquiline in France, Georgia, ...
    File Type:
    Filetype[PDF - 1.25 MB]
  4. Six-Month Response to Delamanid Treatment in MDR TB Patients
    Personal Author:
    Hewison, Cathy; Ferlazzo, Gabriella; Avaliani, Zaza; Hayrapetyan, Armen; Jonckheere, Sylvie; Khaidarkhanova, Zarema; Mohr, Erika; Sinha, Animesh; Skrahina, Alena; Vambe, Debrah; Vasilyeva, Irina; Lachenal, Nathalie; Varaine, Francis;
    Published:
    Oct 17 2017
    Source:
    Emerg Infect Dis. 23(10):1746-1748.
    Description:
    Delamanid, recently available for the treatment of multidrug-resistant tuberculosis (MDR TB), has had limited use outside clinical trials. We present the early treatment results for 53 patients from 7 countries who received a delamanid-containing tre...
    File Type:
    Filetype[PDF - 336.63 KB]
  5. Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis
    Personal Author:
    Achar, Jay; Hewison, Cathy; Cavalheiro, Ana P.; Skrahina, Alena; Cajazeiro, Junia; Nargiza, Parpieva; Herboczek, Krzysztof; Rajabov, Assliddin S.; Hughes, Jennifer; Ferlazzo, Gabriella; Seddon, James A.; du Cros, Philipp;
    Published:
    Oct 17 2017
    Source:
    Emerg Infect Dis. 23(10):1711-1713.
    Description:
    We describe 27 children and adolescents <18 years of age who received bedaquiline during treatment for multidrug-resistant tuberculosis. We report good treatment responses and no cessation attributable to adverse effects. Bedaquiline could be conside...
    File Type:
    Filetype[PDF - 346.30 KB]